5th Annual Cardiovascular Risk Assessment Summit
Examine Regulatory Guidelines and Innovative Approaches to Assess Cardiovascular Risk
January 26 - 27, 2011
Alexandria , VA
Newcardio Inc, although they will not be presenting, they will be there to network.
Some of those that will be in attendance are:
Merat Bagha, President, CEO, Tiba Medical, Inc.
Richard C. Becker, M.D., Professor of Medicine, Divisions of Cardiology and Hematology, Duke University School of Medicine, Duke Clinical Research Institute
Charles I. Berul, M.D., Chief, Division of Cardiology, Children’s National Medical Center; Professor of Pediatrics, George Washington University
Borje Darpo, M.D., Ph.D., Global Medical Director, iCardiac Technologies
Robert P. Fiorentino, M.D., MPH, Medical Officer, Cardiovascular and Renal Products, Food and Drug Administration
Kathleen L. Gabrielson, DVM, Ph.D., Associate Professor, Johns Hopkins University School of Medicine
Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Chairman; QT Working Group, Abbott
David E. Gutstein, M.D., Chair of the Cardiovascular Organ Specific Safety Board, Merck
Jeffrey Heilbraun, MS, Senior Manager, Scientific Affairs, CoreLab Partners Inc.
Luana Pesco Koplowitz, M.D., Ph.D., FCP, FFPM, President, Chief Medical and Scientific Officer, DUCK FLATS Pharma, LLC
Thomas Langenickel, M.D., Ph.D., Medical Director, Discovery Medicine/Cardiovascular and Metabolic Diseases, Co-Chair, CV Advisory Group, Bristol-Myers Squibb
Danshi Li, M.D., Ph.D., Associate Medical Director, Global Pharmacovigilance and Epidemiology, Bristol-Myers Squibb
Catherine MacLeod, M.D., Director of Clinical Research, Department of Clinical Pharmacology, Merck Research Laboratories
Marek Malik, M.D., Ph.D., DSc, FACC, FESC, FHRS, Professor of Cardiac Electrophysiology, St. Paul’s Cardiac Electrophysiology, London
Royce Morrison, M.D., CPI, Director of Clinical Strategy, Charles River Laboratories
Adel Nada, M.D., MS, Director, Clinical Pharmacology Medical Department and Cardiac Safety Clinical Systems, Abbott
Robert Pordy, M.D., FACP, Head, Cardiovascular and Metabolism Therapeutics, Regeneron
Anthony Robinson, MSN, CRNP, Associate Director, Clinical Pharmacology, Shire
Ignacio Rodriguez, M.D., Director, Safety Risk Management, Roche
Jeremy N. Ruskin, M.D., Director, Cardiac Arrhythmia Service, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School
Philip T. Sager, M.D., FACC, FAHA, FHRS, Pharmaceutical Consultant, Chair of the Scientific Oversight Committee, Cardiac Safety Research Consortium
Lawrence Z. Satin, M.D., F.A.C.C., Chief Medical Officer, Cardiocore
Polina Voloshko, M.D., Vice President of Medical Operations, Cardiocore
Robert Wallis, Ph.D., Executive Director, Head of Centres of Emphasis, Drug Safety Research and Development, Pfizer
